Considering this promising improvement in mPFS with acceptable adverse events, a global phase II trial (NCT04619004) aiming to evaluate safety and efficacy of Patritumab deruxtecan as a single agent for EGFRm NSCLC patients whose disease progressed after EGFR-TKIs treatment is ongoing [53]. Here, EGFR is linked to non-small cell lung carcinoma.